Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by 724Capitalon May 19, 2021 12:48pm
119 Views
Post# 33230564

RE:RE:New interview today

RE:RE:New interview todayThank you CapeBretonGirl - I enjoyed the interface this morning with James Howard-Tripp on an InvestorTalk.com this morning that we host every Tues-Thurs pre-market. As I was telling one friend, we are exceptionally supportive of being able to access the Aristotle test for so many reasons its hard to know where to begin or end, other than early cancer detection benefits us all.

Chris Thompson's style I love. The interviews and columns he writes and hosts are authentic, and its clear that he has invested a lifetime into understanding the capital markets -- this was indeed a good interview - eResearch's Chris Thompson with James Howard-Tripp on StageZero’s COVID-... https://youtu.be/p3Ye2IYZDHQ via @YouTube


I am a shareholder.


<< Previous
Bullboard Posts
Next >>